Treatment of conditions related to shock

Abstract

Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.

What is claimed is: 
     
         1 . A method for treating or preventing septic shock in an individual in need thereof, the method comprising administering to a peritoneum of the individual a therapeutic dose of: (i) a pancreatic digestive enzyme inhibitor, (ii) a cytotoxic mediator inhibitor, (iii) an antibacterial agent, or (iv) a combination of two or more thereof. 
     
     
         2 . The method of  claim 1 , further comprising administering to the individual a therapeutic dose of an MMP inhibitor. 
     
     
         3 . The method of  claim 1 , wherein the MMP inhibitor is doxycycline. 
     
     
         4 . The method of  claim 1 , further comprising administering to an intestine of the individual a therapeutic dose of: (i) a serine protease inhibitor, (ii) a lipase inhibitor, or (iii) a combination thereof. 
     
     
         5 . The method of  claim 1 , comprising administering the pancreatic digestive enzyme inhibitor. 
     
     
         6 . The method of  claim 5 , wherein the pancreatic digestive enzyme inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, orlistat, or a combination of two or more thereof. 
     
     
         7 . The method of  claim 6 , wherein the pancreatic digestive enzyme inhibitor is tranexamic acid. 
     
     
         8 . A method for treating or preventing septic shock in an individual in need thereof, the method comprising administering into a lumen of an intestine of the individual a therapeutic dose of a serine protease inhibitor. 
     
     
         9 . The method of  claim 8 , wherein the serine protease inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, or 6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate. 
     
     
         10 . The method of  claim 9 , wherein the serine protease inhibitor is tranexamic acid. 
     
     
         11 . The method of  claim 8 , wherein administering into a lumen of an intestine comprises oral administration, introduction via an esophageal catheter, or direct injection into the lumen of the intestine. 
     
     
         12 . The method of  claim 8 , further comprising administering to the peritoneal cavity of the individual a therapeutic dose of a pancreatic digestive enzyme inhibitor. 
     
     
         13 . The method of  claim 12 , wherein the pancreatic digestive enzyme inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, orlistat, or a combination of two or more thereof. 
     
     
         14 . The method of  claim 12 , wherein the pancreatic digestive enzyme inhibitor is a serine protease inhibitor. 
     
     
         15 . The method of  claim 14 , wherein the serine protease inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, or 6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate. 
     
     
         16 . The method of  claim 15 , wherein the serine protease inhibitor is tranexamic acid. 
     
     
         17 . A method for treating or preventing septic shock in an individual in need thereof, the method comprising administering to the peritoneum of the individual a therapeutic dose of a serine protease inhibitor. 
     
     
         18 . The method of  claim 17 , wherein the serine protease inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, or 6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate. 
     
     
         19 . The method of  claim 18 , wherein the serine protease inhibitor is tranexamic acid.